8-K: Biotricity Completes Second Closing of Private Placement, Secures Additional $500,000

Biotricity Inc. has successfully completed the second closing of its private placement, securing an additional $500,000 through the sale of Series B Preferred Stock.

Summary

• Biotricity Inc. has completed the second closing of a private placement, issuing 55 shares of Series B Convertible Preferred Stock.
• The shares were sold at a price of $9,090.91 each, resulting in gross proceeds of $500,000.
• This follows the first closing on June 24, 2024, which also raised $500,000.
• The company has an agreement with the investor to potentially purchase an additional 165 shares for up to $1,500,000.
• Biotricity is required to seek stockholder approval for the conversion of the Series B Preferred Stock.
• The company will hold a meeting for this purpose no later than August 15, 2024, and every three months thereafter until approval is obtained.

Sentiment

Score: 7

Explanation: The document indicates a positive development with the successful closing of the second tranche of the private placement, securing additional funding. However, the need for shareholder approval and the potential for further capital raises introduce some uncertainty.

Positives

• The company has successfully secured an additional $500,000 in funding.
• There is a potential for further funding of up to $1,500,000.
• The private placement demonstrates investor confidence in the company.

Negatives

• The company needs to obtain stockholder approval for the conversion of the Series B Preferred Stock, which could introduce uncertainty.
• The company is required to hold regular meetings to obtain stockholder approval if it is not obtained at the first meeting.

Risks

• Failure to obtain stockholder approval for the conversion of the Series B Preferred Stock could impact the company's financial plans.
• The company is reliant on a single institutional investor for this funding round.
• The company may need to continue to seek additional funding if the full $2,000,000 is not secured.

Future Outlook

The company intends to seek stockholder approval for the conversion of the Series B Preferred Stock and may pursue further funding through the sale of additional shares.

Management Comments

• The company has agreed to seek the approval of the company's stockholders that may be required upon conversion of the Series B Preferred Stock.

Industry Context

Private placements are a common method for companies, particularly those in the growth phase, to raise capital without the complexities of a public offering. This is a typical funding strategy for companies in the biotech sector.

Comparison to Industry Standards

• Private placements are a common method for biotech companies to raise capital, especially when they are not yet profitable or have limited access to traditional debt markets.
• The terms of the private placement, such as the price per share and the potential for additional funding, are typical for this type of transaction.
• The requirement for stockholder approval for the conversion of preferred stock is a standard practice to protect shareholder interests.

Stakeholder Impact

• Shareholders will need to vote on the conversion of the Series B Preferred Stock.
• The additional funding may allow the company to pursue its business objectives.
• The potential for further funding could dilute existing shareholders if the additional shares are issued.

Next Steps

• The company will hold a stockholder meeting to seek approval for the conversion of the Series B Preferred Stock.
• The company may pursue the sale of an additional 165 shares of Series B Preferred Stock for up to $1,500,000.

Key Dates

Keywords

Private Placement, Series B Preferred Stock, Convertible Preferred Stock, Institutional Investor, Stockholder Approval, Funding, Capital Raise